Carbohydrate antigen 125 combined with N-terminal pro-B-type natriuretic peptide in the prediction of acute heart failure following ST-elevation myocardial infarction
Open Access
- 2 December 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (48) , e32129
Abstract
The value of serum carbohydrate antigen 125 (CA125) combined with N-terminal pro-B-type natriuretic peptide (NT-proBNP) in the evaluation of acute heart failure (AHF) after ST-segment elevation myocardial infarction (STEMI) remains unclear. The aim of this study was to evaluate the efficacy of CA125 combined with NT-proBNP in predicting AHF following STEMI. A total of 233 patients with STEMI were evaluated, including 39 patients with Killip II-IV and 194 patients with Killip I. The optimal cutoff point for predicting AHF was determined by receiver operating characteristic (ROC) curve, and the independent predictors of AHF were evaluated by multiple logistic regression. According to the cutoff value, it was divided into three groups: C1 = CA125 < 13.20 and NT-proBNP < 2300 (n = 138); C2 = CA125 ≥ 13.20 or NT-proBNP ≥ 2300 (n = 59); C3 = CA125 ≥ 13.20 and NT-proBNP ≥ 2300 (n = 36). Differences between groups were compared by odds ratio (OR). The levels of CA125 and NT-proBNP in AHF group were higher than those in non-AHF group (19.90 vs 10.00, P < .001; 2980.00 vs 1029.50, P < .001, respectively). The optimal cutoff values of CA125 and NT-proBNP for predicting AHF were 13.20 and 2300, both of which were independent predictors of AHF. The incidence of AHF during hospitalization was highest in C3 (69.44%), middle in C2 (20.34%) and lowest in C1 (1.45%). After adjustment for clinical confounding variables, compared with C1: C2 (OR = 6.41, 95% CI: 1.22–33.84, P = .029), C3 (OR = 19.27, 95% CI: 3.12–118.92, P = .001). Elevated CA125 and NT-proBNP are independent predictors of AHF in STEMI patients, and their combination can improve the recognition efficiency.Keywords
This publication has 21 references indexed in Scilit:
- Carbohydrate Antigen-125–Guided Therapy in Acute Heart FailureJACC: Heart Failure, 2016
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureEuropean Heart Journal, 2016
- Long-term serial kinetics of N-terminal pro B-type natriuretic peptide and carbohydrate antigen 125 for mortality risk prediction following acute heart failureEuropean Heart Journal: Acute Cardiovascular Care, 2016
- Multimarker Risk Stratification in Patients With Acute Myocardial InfarctionJournal of the American Heart Association, 2016
- 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial InfarctionCirculation, 2016
- Carbohydrate antigen-125: additional accuracy in identifying patients at risk of acute heart failure in acute coronary syndromeCoronary Artery Disease, 2009
- Acute Heart Failure in Patients with Acute Myocardial Infarction Treated with Primary Percutaneous Coronary InterventionEuropean Journal of Heart Failure, 2008
- Acute Pulmonary EdemaNew England Journal of Medicine, 2005
- Predictors of Hospital Mortality in the Global Registry of Acute Coronary EventsArchives of internal medicine (1960), 2003
- Predictive value of the Killip classification in patients undergoing primary percutaneous coronary intervention for acute myocardial infarctionThe American Journal of Cardiology, 2001